Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
The likelihood of clinicians prescribing direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C virus (HCV) and substance use disorder (SUD) was assessed via a survey emailed throughout the United States to clinicians (physicians and advanced practice providers) in gastroenterol...
Main Authors: | Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera, Robert L. Cook |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-04-01
|
Series: | Preventive Medicine Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211335523000293 |
Similar Items
-
Medicaid Expansion Case Study: Differences Between Florida and New York Medicaid Expansion Policy
by: Mary Zielinski, et al.
Published: (2024-07-01) -
Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01) -
Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022-02-01) -
HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
by: Curtis L. Cooper, et al.
Published: (2019-08-01) -
Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-10-01)